[Edaily Reporter Lee Hye-ra] #LabGenomics announced on the 12th that its largest shareholder, “Ruhagalacticos,” has purchased shares on the open market to stabilize the stock price and demonstrate responsible management. Ruhagalacticos is a special purpose company (SPC) established by Ruhape.

Through this on-market purchase, Luha Galacticos increased its stake in LabGenomics from approximately 16% to approximately 19%. The total value of this on-market purchase was 2 billion won.
Since acquiring LabGenomics, Ruha PE has been pursuing strategies to enhance the company’s value over the medium to long term, including expanding the NGS (next-generation sequencing) diagnostics business based on U.S. CLIA-certified laboratories and broadening strategic partnerships with major domestic pharmaceutical companies. This increase in shareholding demonstrates the largest shareholder’s confidence in these growth strategies and its commitment to responsible management. The company explained that this move reflects its confidence in LabGenomics’ future growth potential and the possibility of a normalization of its valuation.
A representative from Ruha PE commented on this decision, stating, “We judged that the current stock price is significantly undervalued relative to the company’s intrinsic value and growth potential due to factors such as the global economic slowdown and the downturn in the biotech sector.” They added, “We will use this increase in our stake as an opportunity to clearly demonstrate our commitment to responsible management and continue to provide full support so that our business performance and efforts to enhance shareholder value are properly recognized by the market.”
LabGenomics recently successfully secured a 20 billion won investment in convertible bonds (CBs) from Stick Investment, a major domestic private equity fund (PEF) manager. Building on this, the company plans to accelerate its expansion into domestic and international molecular diagnostics markets—including next-generation sequencing (NGS) diagnostics through its U.S. subsidiary—and use this to drive a medium- to long-term turnaround in its performance.